Selecta Biosciences (SELB) PT Lowered to $5 at Needham & Company

June 14, 2022 6:36 AM EDT
Get Alerts SELB Hot Sheet
Price: $2.32 -1.69%

Rating Summary:
    9 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 29 | New: 9
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Needham & Company analyst Gil Blum lowered the price target on Selecta Biosciences (NASDAQ: SELB) to $5.00 (from $6.00) while maintaining a Buy rating.

The analyst commented, "Selecta reported an extension for its option agreement with Sarepta to 1Q:23 for use of ImmTOR in Duchenne Muscular Dystrophy (DMD) and certain Limb-Girdle Muscular Dystrophies (LGMD) programs. The extension triggers a $2M payment from Sarepta. An additional $4M payment is contingent on meeting certain preclinical milestones by Sarepta. DISSOLVE II in chronic refractory gout is on track to complete enrollment by 2Q. The company is eligible to receive $10M milestone payment upon completion of enrollment. Joint topline data for DISSOLVE I and II remain on track for 1Q:23. Selecta now expects to start SEL-302 Phase I study in methylmalonic acidemia (MMA) in 4Q:22 (previously 2H:22). We maintain our Buy rating but decrease our Target to $5 from $6 for (1) slightly lowered near term revenues and (2) changing interest rate environment."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Needham & Company